- Report
- August 2023
- 70 Pages
South Korea
From €4486EUR$4,750USD£3,817GBP
- Report
- October 2022
- 70 Pages
Africa
From €4486EUR$4,750USD£3,817GBP
- Report
- February 2024
- 143 Pages
Global
From €4486EUR$4,750USD£3,817GBP
- Report
- February 2024
- 85 Pages
North America
From €4486EUR$4,750USD£3,817GBP
- Report
- August 2023
- 150 Pages
North America
From €4486EUR$4,750USD£3,817GBP
- Report
- March 2019
- 90 Pages
Europe
From €4486EUR$4,750USD£3,817GBP
- Report
- February 2022
- 195 Pages
Global
From €3400EUR$3,600USD£2,893GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €472EUR$500USD£402GBP
Humalog is a brand of insulin used to treat diabetes, a chronic endocrine and metabolic disorder. It is a fast-acting insulin that helps to control blood sugar levels in people with type 1 and type 2 diabetes. Humalog is a recombinant human insulin analog, meaning it is a synthetic version of the natural human insulin. It is administered via injection and works by helping the body to use glucose from the bloodstream. Humalog is used to help control blood sugar levels in people with diabetes, and can be used in combination with other diabetes medications.
Humalog is available in a variety of forms, including vials, pens, and cartridges. It is manufactured by Eli Lilly and Company, and is available in many countries around the world. Other companies that produce insulin analogs include Novo Nordisk, Sanofi, and Biocon. Show Less Read more